Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Lipocine Inc. (LPCN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
08/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis ● Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index relative to placebo events of grade >1 in the LPCN 1148 treatment arm relative to placebo , a biopharmaceutical company focused on treating Central Nervous System disorders by leveraging its proprietary platform to develop differentiated products, today announced positive topline results from a Phase 2 clinical study of LPCN 1148. LPCN 1148 is an oral candidate under development for the clinical management of cirrhosis. Lipocine plans to meet with the FDA to discuss a development path to NDA filing. “We are delighted with the positive results from our Phase 2 study,” said Dr. Mahesh Patel, President and CEO of Lipocine Inc. “Man..."
06/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023 SALT LAKE CITY, June 7, 2023 — Lipocine Inc. , a biopharmaceutical company focused on treating Central Nervous System disorders by leveraging its proprietary technology platform to develop differentiated products, today announced that it will present posters on LPCN 1148 and LPCN 1144 at the forthcoming European Association for the Study of the Liver Congress 2023 , to take place in Vienna, Austria, June 21 – 24, 2023. A multimodal treatment candidate for sarcopenia in men with decompensated cirrhosis: a randomized, placebo-controlled trial evaluating LPCN 1148 Lead autho..."
05/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
05/25/2023 4 Patel Mahesh V. (CEO and President) has filed a Form 4 on Lipocine Inc.
Txns: Bought 8,706 shares @ $5.03, valued at $43.8k
05/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine’ s Oral Candidate for Rapid Relief of Depression"
05/12/2023 4 Papapetropoulos Spyros (Director) has filed a Form 4 on Lipocine Inc.
Txns: Granted 30,000 options to buy @ $0.2656, valued at $8k
05/12/2023 4 Higuchi John W. (Director) has filed a Form 4 on Lipocine Inc.
Txns: Granted 30,000 options to buy @ $0.2656, valued at $8k
05/12/2023 4 Ono Richard Dana (Director) has filed a Form 4 on Lipocine Inc.
Txns: Granted 30,000 options to buy @ $0.2656, valued at $8k
05/12/2023 4 Jene Jill M. (Director) has filed a Form 4 on Lipocine Inc.
Txns: Granted 30,000 options to buy @ $0.2656, valued at $8k
05/12/2023 4 Fink Jeffrey Arvin (Director) has filed a Form 4 on Lipocine Inc.
Txns: Granted 30,000 options to buy @ $0.2656, valued at $8k
05/11/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "FOURTH:"
05/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 SALT LAKE CITY, May 11, 2023 – Lipocine Inc. , a biopharmaceutical company focused on treating Central Nervous System disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update. First Quarter Highlights Neuroactive Steroid for Depression Dosing was initiated in a pilot clinical bridge study of LPCN 1154 a neuroactive steroid product candidate that Lipocine is developing for postpartum depression . LPCN 1154 is targeted to be a differentiated oral treatment option as a mono or add-on therapy for patients with unresolved symptoms needing fast onset with high response in short tre..."
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
04/03/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154 ● LPCN 1154 is an oral formulation of brexanolone in development for the rapid relief of postpartum depression ● Topline study results expected in H1 2023 SALT LAKE CITY, April 3, 2023 — Lipocine Inc. , a biopharmaceutical company focused on treating Central Nervous System disorders by leveraging its proprietary platform to develop differentiated products, today announced that the first participant has been dosed in a pilot clinical bridge study of LPCN 1154 and approved injectable brexanolone. The U.S. Food and Drug Administration has agreed with Lipocine’ s proposal for establishing the efficacy and safety of LPCN 1154 in women with PPD through a clinical bridge to an approved IV in..."
03/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/24/2023 4 Patel Mahesh V. (CEO and President) has filed a Form 4 on Lipocine Inc.
Txns: Bought 150,000 shares @ $0.32, valued at $48k
03/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/20/2023 ARS Form ARS - Annual Report to Security Holders:
03/17/2023 4 Patel Mahesh V. (CEO and President) has filed a Form 4 on Lipocine Inc.
Txns: Bought 50,000 shares @ $0.33, valued at $16.5k
03/17/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/10/2023 10-K Annual Report for the period ended December 31, 2022
03/10/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF LIPOCINE INC.",
"LIPOCINE INC. CERTIFICATE OF DESIGNATION OF SERIES B PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Lipocine Inc., a Delaware corporation , that the following resolution was duly adopted by the board of directors of the Corporation , in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, as amended , at a meeting duly called and held on March 7, 2023, which resolution provides for the creation of a series of the Corporation’ s Preferred Stock, par value $0.001 per share, which is designated as “Series B Preferred Stock,” with the rights, powers and preferences, and the qualifications, limitations and restrictions thereof, set forth therein. W...",
"Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock"
03/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lipocine Announces Financial Results for the Year Ended December 31, 2022 SALT LAKE CITY, March 10, 2023 – Lipocine Inc. , a biopharmaceutical company focused on treating Central Nervous System disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the year ended December 31, 2022 and provided a corporate update. In 2022, Lipocine announced a new strategic direction, focusing on the development of endogenous neuroactive steroids which have broad applicability in treating various CNS conditions. The Company is currently exploring partnering non-core assets including LPCN 1107, for prevention of pre-term birth, LPCN 1148, for the management of decompensated cirrhosis, LPCN 1144, for treatment of non-cirrhotic NASH, LPCN 1111..."
03/10/2023 8-A12G Form 8-A12G - Registration of securities [Section 12(g)]:
01/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
01/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
01/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lipocine to Present at Biotech Showcase Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY, January 5, 2023 — Lipocine Inc. , a biopharmaceutical company focused on treating Central Nervous System disorders by leveraging its proprietary platform to develop differentiated products, today announced that its management will present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners. Both in-person events will take place January 9-11, 2023, in San Francisco, California. Biotech Showcase: Date: Tuesday, January 10 and Wednesday, January 11 Presentation: Wednesday, January 11, 9AM Pacific Time Location: Yosemite A Level Ballroom, Hilton Hotel Uni..."
01/04/2023 4 Patel Mahesh V. (CEO) has filed a Form 4 on Lipocine Inc.
Txns: Granted 300,000 options to buy @ $0.41, valued at $123k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy